Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

He-Rui Yao · SciRah

Researcher profile · Semantic Scholar

He-Rui Yao

Share profile

He-Rui Yao — researcher profile on SciRah

h-index: 8
Works: 33
Citations: 260

Most-cited papers

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
S. Loibl, Y. Park, Z. Shao, Chiun-Sheng Huang +26 more
2025New England Journal of Medicine70 citations
Semantic Scholar
Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial
Yang-Qing Zhan, Zheng-Shi Lin, Jingyi Liang, Ruilin Sun +35 more
2023EClinicalMedicine48 citations Open access
Semantic Scholar
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
He-Rui Yao, M. Yan, Z. Tong, Xin-Hong Wu +29 more
2024Journal of Clinical Oncology42 citations
Semantic Scholar
Phase I clinical trial of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of advanced breast cancer.
Yi-Guang Lin, H. Yin, Chao Zhou, Ling Zhou +2 more
2024Journal of Clinical Oncology18 citations Open access
Semantic Scholar
Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system
Xiu-Juan Gui, Jian-Li Zhao, Linxiaoxiao Ding, Jie Chai +8 more
2023Frontiers in Oncology17 citations Open access
Semantic Scholar
Efficacy and safety of KN026 and docetaxel for HER2‐positive breast cancer: a phase II clinical trial
Jian-Li Ma, Jingxuan Wang, Ting Xu, Q. Ouyang +17 more
2025Cancer Communications14 citations Open access
Semantic Scholar
First-in-human study of JSKN016, a bispecific anti-TROP2/HER3 antibody drug conjugate (ADC): Antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results.
He-Rui Yao, Jieqiong Liu, Yin-Duo Zeng, Zhang-Zhou Huang +16 more
2025Journal of Clinical Oncology11 citations
Semantic Scholar
Nanoparticles (NPs)-mediated silencing of GSTP1 expression to reverse chemoresistance for effective breast cancer therapy.
Q. Shen, Ke Yang, Qing-Jian Li, Tao Qin +4 more
2025Journal of Colloid and Interface Science9 citations
Semantic Scholar
SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial
He-Rui Yao, M. Yan, Z. Tong, Xin-Hong Wu +28 more
2026Signal Transduction and Targeted Therapy6 citations Open access
Semantic Scholar
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases
Shaohua Zhang, Yong-Mei Yin, Hailin Xiong, Jing-Fen Wang +35 more
2024JAMA Oncology6 citations Open access
Semantic Scholar
Abstract PO2-04-03: BL-M07D1, an antibody-drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study
Erwei Song, He-Rui Yao, Mei-Li Sun, Hong Zong +9 more
2024Cancer Research4 citations
Semantic Scholar
Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer.
Fei Ma, Xiaoxiang Guan, Jing-Fen Wang, He-Rui Yao +10 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
Phase I Trial of Upamostat Combined With Gemcitabine in Locally Unresectable or Metastatic Pancreatic Cancer: Safety and Preliminary Efficacy Assessment
Xiuping Lai, Di Cheng, Huixin Xu, Jingshu Wang +6 more
2024Cancer Medicine3 citations
Semantic Scholar
JSKN016, a first-in-class anti-TROP2/HER3 bispecific antibody-drug conjugate (ADC), in patients (pts) with HER2-negative locally advanced or metastatic breast cancer: Results from a phase I study.
He-Rui Yao, Zhang-Zhou Huang, Hong Zong, M. Yan +16 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer
Jingshu Wang, Xiuping Lai, He-Rui Yao, Hui Yang +12 more
2025Journal of Cancer Research and Clinical Oncology2 citations Open access
Semantic Scholar
The safety, tolerability, and efficacy of BRY812 in patients with advanced solid tumors: Preliminary results from the phase I clinical study.
He-Rui Yao, M. Yan, Jing-Na Wu, Hong Wang +14 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
Establishing an evaluation index system of nursing quality for clinical drug trials: A Delphi study
Junyi Chen, Huiyu Zhou, Qingxiu Mai, Shu-Ping Chen +7 more
2023Nursing Open2 citations Open access
Semantic Scholar
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.
He-Rui Yao, Qing-Yuan Zhang, Hui-Ping Li, Yong-Mei Yin +37 more
2026The Lancet Oncology1 citations
Semantic Scholar
Abstract PS8-01: ZN-1041, a potential best-in-class BBB Penetrable HER2 Inhibitor, has high antitumor activity in patients with Breast Cancer with CNS Metastases
Di Zhu, Fei Ma, Yi-Qun Li, He-Rui Yao +16 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Abstract PS8-06: A randomized, open-label phase III study comparing disitamab vedotin (an anti-HER2 monoclonal antibody-MMAE conjugate) with lapatinib plus capecitabine in patients with HER2-positive, advanced breast cancer with liver metastasis
Jia-Yu Wang, Q. Ouyang, Wei-Min Xie, Zhao-Feng Niu +23 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Association of LIV-1 expression with clinical efficacy in patients with advanced breast cancers treated with BRY812.
Erwei Song, Haochuan Zheng, Hailong Zhang, Jingtao Lu +13 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
Abstract PO1-06-10: Overall survival results from EVER-132-001, a phase 2b single-arm study of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer
Fei Ma, Shu-Sen Wang, Z. Tong, Wei Li +16 more
2024Cancer Research1 citations
Semantic Scholar
A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody–drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours
He-Rui Yao, Rui-Hua Zhao, Xiuping Lai, Qing Wen +19 more
2026EBioMedicine0 citations Open access
Semantic Scholar
Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial
Jia-Yi Wang, Q. Ouyang, Wei-Min Xie, Zhao-Feng Niu +24 more
2026Nature Communications0 citations Open access
Semantic Scholar
Phase II study of T-Bren (BL-M07D1) monotherapy or in combination with pertuzumab in patients with treatment-naïve HER2-positive unresectable locally advanced or metastatic (LA/M) breast cancer.
He-Rui Yao, Yehui Shi, Yuemei Mo, Ya-Ping Yang +16 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer
Xiu-Juan Gui, Haizhu Chen, Jian-Li Zhao, Hongna Lai +9 more
2026Therapeutic Advances in Medical Oncology0 citations Open access
Semantic Scholar
Abstract CT074: A phse 1 study of CAN2109, a novel,long-acting, tumor-retained, immunoegenic cell death inducer
He-Rui Yao, Ning Li, H. Yu, Giorgio Massimini +11 more
2026Cancer Research0 citations
Semantic Scholar
Abstract PS8-08: Efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate (ADC), in 391 heavily pretreated multiple solid tumors with HER2-expression or mutations: a global, multi-center, first-in-human, phase 1 study
He-Rui Yao, M. Yan, Z. Tong, Xin-Hong Wu +26 more
2025Clinical Cancer Research0 citations
Semantic Scholar
689 Results from a phase I dose escalation trial of CAN1012 in patients with solid tumors
H. Yu, He-Rui Yao, Ning Li, Shu-Hang Wang +12 more
2024Regular and Young Investigator Award Abstracts0 citations Open access
Semantic Scholar
A single-arm, multicenter, phase II study of utidelone in advanced solid tumors: Efficacy data from screening and the expansion cohort assessing utidelone plus sintilimab and oxaliplatin for advanced gastric cancer.
Mei-Li Sun, He-Rui Yao, Ying Zhou, Hua Chen +7 more
2024Journal of Clinical Oncology0 citations
Semantic Scholar
Abstract RF02-05: Report on Cohort Expansion of Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of BB-1701 in Patients with Locally Advanced/Metastatic HER2 Low Breast Cancer
Fei Ma, Pamela N. Munster, Xiaoxiang Guan, Jing-Fen Wang +9 more
2024Cancer Research0 citations
Semantic Scholar
Corrigendum: Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390
Xiao-Zhi Lv, Jun-Yan Wu, He-Rui Yao, Sui-Wen Ye +1 more
2024Frontiers in Drug Discovery0 citations Open access
Semantic Scholar
763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies
H. Yu, He-Rui Yao, Ning Li, Shu-Hang Wang +13 more
2023Regular and Young Investigator Award Abstracts0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Z. Tong×8
Invite
Z. Tong — researcher profile on SciRah
Sui-Wen Ye×8
Invite
Sui-Wen Ye — researcher profile on SciRah
Erwei Song×8
Invite
Erwei Song — researcher profile on SciRah
M. Yan×7
Invite
M. Yan — researcher profile on SciRah

×7

Invite

Xin-Hong Wu — researcher profile on SciRah

Jing-Fen Wang×7

Invite

Jing-Fen Wang — researcher profile on SciRah

Invite

Jun-Yan Wu — researcher profile on SciRah

Qing-Yuan Zhang×6

Invite

Qing-Yuan Zhang — researcher profile on SciRah

Yong-Mei Yin×5

Invite

Yong-Mei Yin — researcher profile on SciRah

Invite

Q. Ouyang — researcher profile on SciRah

Invite

Ying Wang — researcher profile on SciRah

Invite

Xiuping Lai — researcher profile on SciRah